Table 2.

Novel agent–based salvage regimens in second-line therapy in cHL

RegimenPhaseNPrimary refractory, nRelapsed, nCMR, %PFS, %Reference
BV based salvage regimens        
 Sequential BV and chemotherapy        
  BV→augmented ICE 2 45 25 20 76* 82 at 3 y 44 
  BV→salvage therapy 2 57 35 22 74† 71 at 2 y 45 
 Combination BV and chemotherapy/ novel agents        
  BV + ICE        
   BV-ICE x 2 1/2 16 11 5 69 Not reported 47 
   BV-ICE x 2-3 2 42‡ 12 30 69 69 at 1 y 48 
  BV + ESHAP 1/2 66 40 26 70 71 at 30 mo 49 
  BV + DHAP 2 55 23 32 81 74 at 2 y 50 
  BV + Gemcitabine 1/2 45§ 29 16 67 Not reached 51 
  BV + bendamustine 1/2 55 28 27 74 62.6 at 2 y 52 
  BV + nivolumab 1/2 91 38 53 67 77 at 3 y 53,54 
Anti–PD-1 based salvage regimens        
 N±ICE‖ 2 39 18 21 86 79 at 1 y 58 
 Pem-ICE 2 23 8 15 96 Not reported 59 
 Pem-GVD# 2 39 16 23 95 Not reached 60,61 
RegimenPhaseNPrimary refractory, nRelapsed, nCMR, %PFS, %Reference
BV based salvage regimens        
 Sequential BV and chemotherapy        
  BV→augmented ICE 2 45 25 20 76* 82 at 3 y 44 
  BV→salvage therapy 2 57 35 22 74† 71 at 2 y 45 
 Combination BV and chemotherapy/ novel agents        
  BV + ICE        
   BV-ICE x 2 1/2 16 11 5 69 Not reported 47 
   BV-ICE x 2-3 2 42‡ 12 30 69 69 at 1 y 48 
  BV + ESHAP 1/2 66 40 26 70 71 at 30 mo 49 
  BV + DHAP 2 55 23 32 81 74 at 2 y 50 
  BV + Gemcitabine 1/2 45§ 29 16 67 Not reached 51 
  BV + bendamustine 1/2 55 28 27 74 62.6 at 2 y 52 
  BV + nivolumab 1/2 91 38 53 67 77 at 3 y 53,54 
Anti–PD-1 based salvage regimens        
 N±ICE‖ 2 39 18 21 86 79 at 1 y 58 
 Pem-ICE 2 23 8 15 96 Not reported 59 
 Pem-GVD# 2 39 16 23 95 Not reached 60,61 

CMR was determined by PET scan.

DHAP, dexamethasone, cytarabine, cisplatin; ESHAP, etoposide, cytarabine, cisplatin, methylprednisolone; N±ICE, nivolumab with or without ICE.

*

27% achieved CMR to BV alone, and 76% to both.

†

43% achieved CMR to BV alone, and 74% to both.

‡

Only 39 patients were evaluable for efficacy.

§

Only 42 patients were evaluable for efficacy.

‖

Patients received nivolumab 3 mg/kg every 2 weeks for 6 cycles. Patients in CR at cycle 6 proceeded to auto-HCT; those not in CR received nivo+ICE for 2 cycles.

End of nivolumab alone CR rate, 70%; end of nivo+ICE CR rate, 86%.

#

Thirty-seven patients were evaluable for response.

View Large